Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

Bristol Myers Squibb announced that ZENBEXUS (iberdomide) combined with daratumumab and dexamethasone (ZDd) demonstrated superior results, but the provided headline is truncated before specifying the comparison, endpoint, or magnitude. The limited information supports a mildly positive read on the clinical update, with its significance difficult to assess.